Latest Strategic Focus News

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

QuickFee Limited’s FY26 results show stable normalised revenue with Australian loan originations surging 40%, offsetting US finance declines. The company ups its Australian debt facility and confirms EBITDA guidance, eyeing growth in both markets.

AdNeo Limited achieved a record positive operating cash flow of $451k in Q4 FY26 and secured significant customer contracts, setting the stage for disciplined growth in FY27.

Pacgold's latest drilling at the Vertigo deposit uncovers strong shallow oxide gold mineralisation, accelerating plans to restart mining at White Dam. An updated resource estimate is due early Q3 2026.

AuKing Mining has rapidly advanced its Tundulu Rare Earths Project in Malawi, confirming extensive carbonatite mineralisation beyond historical targets and securing $8 million to fund an expanded drilling campaign including diamond drilling.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

True North Copper (ASX:TNC) has agreed to sell its Bundarra Copper Project to Tec Minerals, securing A$500,000 cash, A$1 million equity in Tec Minerals, and a 1% Net Smelter Royalty, as it sharpens focus on its Mt Oxide and Cloncurry copper developments.

Perenti's subsidiary AMS, through AMAX Ltd, has secured a six-month contract extension at the Iduapriem Gold Mine in Ghana, including the sale of mining equipment valued between A$30 million and A$40 million to AngloGold Ashanti.

St Barbara Limited reported an 8% increase in gold production for Q4 FY26, with attributable output from New Simberi Gold beating previous guidance. The company maintains a robust balance sheet with A$509 million in cash, bullion, and listed investments, while remaining debt-free.

Starpharma Holdings is raising approximately $32 million through a fully underwritten 1-for-7.5 renounceable entitlement offer priced at $0.57 per share, discounting the stock by 25%. Proceeds will fund the DEP HER2-Lu Phase 1 trial and expand its dendrimer-based oncology pipeline.

Metal Hawk has resumed reverse circulation drilling at its Leinster South Project, aiming to expand on recent high-grade gold intercepts at the Thylacine and Tysons prospects. The campaign is expected to last up to three weeks, with assay results due in about a month.

True North Copper is advancing its Mt Oxide Project with a strategic focus on expanding the Aquila copper-cobalt-silver discovery and developing the high-grade Vero resource, aiming to emulate the scale of the nearby Capricorn Copper mine.